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A Family History of Lethal 
Prostate Cancer and Risk of 
Aggressive Prostate Cancer in 
Patients Undergoing Radical 
Prostatectomy
Omer A. Raheem, Seth A. Cohen, J. Kellogg Parsons, Kerrin L. Palazzi & 
Christopher J. Kane
We investigated whether a family history of lethal prostate cancer (PCa) was associated with high-
risk disease or biochemical recurrence in patients undergoing radical prostatectomy. A cohort of 
radical prostatectomy patients was stratified into men with no family history of PCa (NFH); a first-
degree relative with PCa (FH); and those with a first-degree relative who had died of PCa (FHD). 
Demographic, operative and pathologic outcomes were analyzed. Freedom from biochemical 
recurrence was examined using Kaplan-Meier log rank. A multivariate Cox logistic regression analysis 
was also performed. We analyzed 471 men who underwent radical prostatectomy at our institution 
with known family history. The three groups had: 355 patients (75%) in NFH; 97 patients (21%) in 
FH; and 19 patients (4%) in FHD. The prevalence of a Gleason score ≥ 8, higher pathologic T stage, 
and biochemical recurrence (BCR) rates did not significantly differ between groups. On Kaplan-Meier 
analysis there were no differences in short-term BCR rates (p = 0.212). In this cohort of patients 
undergoing radical prostatectomy, those with first-degree relatives who died of PCa did not have an 
increased likelihood of high-risk or aggressive PCa or shorter-term risk of BCR than those who did 
not.
Prostate cancer (PCa) risk stratification is critical to help physicians and patients decide whether they 
require treatment and what treatment might be best. Interestingly, family history of PCa, one of the few 
known risk factors for the disease, is not associated with worse disease at diagnosis or a worse outcome 
after treatment1,2. However, the lethality of a patient’s family history, that is whether their first-degree 
relatives died of the disease, may influence the assignment of PCa risk and fear of adverse outcomes in 
both patients and physicians3–5.
Approximately 10% to 20% of patients with localized PCa are reported to present with a positive fam-
ily history of PCa. Although it has been clearly described as a finding more common in younger versus 
older men, there is still significant controversy about the importance of the presence of a positive family 
history of PCa with respect to presentation and prognosis.
At the genetic level, the association of family history and PCa has been established by characterization 
of single-nucleotide polymorphisms (SNP) associated with PCa and the recent discovery of the HOXB13 
G84E variant, a germline mutation, associated with increased risk of hereditary PCa6–9. In addition to 
understanding the link between prevalence and genetics, it would be informative to understand the 
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impact family history of prostate cancer-specific mortality has on the character of the disease process 
itself.
We sought to determine if lethality of family history (having a first-degree relative die of PCa) is 
associated with more aggressive PCa clinically or pathologically.
Patients and Methods
In this study, in which all experimental protocols were approved by the Institutional Review Board of 
the University of California, San Diego and carried out in accordance with the approved guidelines, we 
analyzed prospectively collected data from patients undergoing radical prostatectomy, including open 
and robotic assisted laparoscopic, performed by different surgeons at UC San Diego Health System. We 
identified three groups: 1) men with no family history of PCa (NFH); 2) a first-degree relative with PCa 
who had survived the disease (FH); and 3) those with a first-degree relative who had died of PCa (FHD). 
Death from PCa in the first-degree relatives was confirmed by analysis of the source electronic health 
record. Informed consent was obtained from all subjects. In addition, individual phone calls were made 
to patients confirming when cause of death in a first-degree relative was documented as a result of PCa.
Patient demographics, clinical characteristics and prostate cancer risk categories among the three 
groups included age, race, and body mass index (BMI), use of 5-α reductase inhibitors, comorbidities 
(hypertension, hyperlipidemia, coronary artery disease, and diabetes), pre-operative prostate specific 
antigen (PSA), and D’Amico risk stratification. In addition, neoadjuvant and/or concurrent treatment 
was compared among the three groups (Table  1). The operative outcomes and post-operative compli-
cations among the three groups, including total operative time, blood loss, prostate size, use of lym-
phadenectomy, use of nerve-sparing technique, rate of blood transfusion, length of hospitalization, and 
Variables
No Family 
History 
Prostate 
Cancer 
(NFH)
Family 
History 
Prostate 
Cancer Non-
Lethal (FH)
Family 
History 
Prostate 
Cancer Died 
(FHD)
p-value
n = 355 
(75%) n = 97 (21%) n = 19 (4%)
Age ± SD, mean (years) 62 ± 6.7 60 ± 7.4 61 ± 7.6 0.008*
Race 0.041*
 Caucasian 252 (71%) 81 (84%) 13 (69%)
 Other 103 (29%) 16 (17%) 6 (32%)
BMI ± SD, mean (Kg/m2) 27.7 ± 4.2 27.5 ± 3.7 27.2 ± 4.7 0.831
Hypertension 142 (40%) 36 (37%) 5 (26%) 0.454
Hypercholesterolemia 132 (37%) 32 (33%) 3 (16%) 0.140
Diabetes Mellitus (DM) 29 (8%) 6 (6%) 1 (5%) 0.747
Coronary artery disease 19 (5%) 6 (6%) 2 (11%) 0.625
5α -reductase inhibitor (Proscar/Avodart) 24 (7%) 3 (3%) 1 (5%) 0.397
Pre-operative PSA (ng/mL) (IQR), 
median 5.9 (4.2–8.6) 5.3 (4.1–6.6) 5.7 (3.7–6.6) 0.094
Clinical T Stage 0.759
 T1a-c 226 (64%) 67 (70%) 12 (67%)
 T2a-c 120 (34%) 28 (29%) 6 (33%)
 T3a-b 8 (2%) 1 (1%) 0
Biopsy Gleason Score 0.16
 ≤ 6 153 (45%) 55 (59%) 9 (50%)
 7 115 (34%) 23 (25%) 7 (39%)
 ≥ 8 70 (21%) 15 (16%) 2 (11%)
D’Amico risk group 0.099
 Low risk 143 (40%) 52 (54%) 6 (32%)
 Intermediate risk 133 (38%) 28 (29%) 10 (53%)
 High risk 79 (22%) 17 (18%) 3 (16%)
Neoadjuvant/Concurrent treatment 21 (6%) 3 (3%) 0 0.314
Table 1. Patients’ demographic, clinical characteristics and prostate cancer risk stratification among the 
three groups. SD, standard deviation; BMI, body mass index; PSA, prostate specific antigen. *statistically 
significant (p < 0.05).
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rate of post-operative complications are shown in Table  2. The pathologic findings of PCa specimens 
included tumor size, lymph node yield, Gleason score, T-stage, margins status, perineural invasion (PNI), 
extensive prostatic intraepithelial neoplasia (PIN), and lymphovascular invasion (LVI); these were com-
pared among the three cohorts. In addition, post-operative outcomes of the 6-week PSA, use of adjuvant 
treatment, biochemical recurrence, median time to recurrence and median length of follow-up were 
compared.
Demographic, clinical, and pathologic outcomes were compared using Chi2 test, Fisher’s exact test, 
ANOVA, independent T test (Bonferroni correction for pair comparisons), Kruskal-Wallis test, and 
Mann-Whitney U test. Biochemical recurrence outcomes were compared using Kaplan-Meier log rank 
test. Cox logistic regression models were utilized for multivariate analysis to assess for biochemical recur-
rences. All statistics were performed using SPSS v17.0 (SPSS, Inc., Chicago IL) using two-tailed α = 0.05 
as statistically significant.
Results
Between 2008 and 2011, a total of 600 men underwent radical prostatectomy for organ confined PCa 
at the hospitals affiliated with our academic institution. However out of this cohort, a total of 471 men 
had complete database consents and complete family history information and thus were included in this 
study. Study group populations were: 355 patients (75%) in the NFH group, 97 patients (21%) in the FH 
group and 19 patients (4%) in the FHD group.
Men in the FH group were diagnosed slightly younger than men in the NFH and FHD groups 
(p = 0.008). Additionally, more Caucasian men were found in the FH group (84%), compared with the 
other groups (p = 0.04). Overall, the three groups were similar in most demographics, comorbidities 
(BMI, DM, hypertension, hyperlipidemia, coronary artery disease, and 5α -reductase inhibitor use) and 
clinical D’Amico risk stratification. Univariate analysis is shown in Table 1.
With respect to the operative outcomes and post-operative complications, the three groups were com-
parable with the exception of a higher prevalence of peri-operative blood transfusions in FHD (11%, 
p = 0.028) (Table  2). On pathologic analysis, the prevalence of Gleason score ≥ 8 was similar within 
each group. Similarly, the pathologic T stage was comparable across the three groups. In the NFH group, 
however, there was higher prevalence of LVI compared to FH and FHD (11%, p = 0.048).
Biochemical recurrence (BCR) rates were similar for each group: 33/355 patients (9%) in NFH, 5/97 
patients (5%) in FH, and 1/19 patients (5%) in FHD (p = 0.376). Median time to BCR and the pro-
portions of adjuvant therapy utilization did not significantly differ between groups. On Kaplan-Meier 
analysis there were no differences in short-term BCR rates (p = 0.212) (Fig. 1). Overall, the FHD cohort 
of patients had the longest median follow-up.
Multivariate Cox logistic regression analysis was performed to determine the variables affecting BCR 
among groups. Table  3 demonstrates that family history of prostate cancer adjusted for age, race and 
D’Amico risk group did not show significant differences. Furthermore, Table 4 demonstrates that family 
Variables
No Family 
History 
Prostate Cancer 
(NFH)
Family History 
Prostate Cancer 
Non-Lethal 
(FH)
Family History 
Prostate Cancer 
Died (FHD)
p-valuen = 355 (75%) n = 97 (21%) n = 19 (4%)
Median operative time (IQR), 
(minutes) 188 (160–210) 185 (160–209) 180 (166–207) 0.892
Median EBL (IQR), (mL) 150 (100–200) 150 (100–200) 175 (100–200) 0.591
Median prostate weight (IQR), 
gm 48 (38–60) 47 (39–48) 42 (38–48) 0.210
Peri-operative blood 
transfusion (units) 11 (3%) 0 2 (11%) 0.028
*
Lymph nodes dissection 
(node) 190 (54%) 44 (45%) 7 (37%) 0.161
Nerve sparing technique 0.319
None/Partial 68 (20%) 12 (13%) 3 (17%)
Complete 281 (81%) 82 (87%) 15 (83%)
Median hospital stay (IQR), 
(days) 1 (1-1) 1 (1-1) 1 (1-1) 0.471
Post operative complications 85 (24%) 23 (24%) 6 (32%) 0.745
 Low grade complications 75 (21%) 20 (21%) 4 (21%) 0.994
 High grade complications 23 (7%) 4 (4%) 2 (11%) 0.500
Table 2. Operative outcomes and post-operative complications among the three groups. EBL, estimated 
blood loss. *statistically significant (p < 0.05).
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history of prostate cancer adjusted for age, race, PSA, pathologic Gleason score, pathologic T stage, 
margin status and LVI did not demonstrate significant differences.
Discussion
In this prospective study of well-matched radical prostatectomy patients, the NFH, FH and FHD groups 
had similar demographics, comorbidities and D’Amico Risk stratification, allowing for a meaningful 
comparison of operative, pathologic, and treatment outcomes. Operative outcomes were similar in 
almost all respects, including operative time and rate of complication. There was a statistically higher 
rate of blood transfusions in the FHD cohort; the event rate for blood transfusions was so low in all of 
the cohorts, however, that this likely has no clinical significance.
To our knowledge, the relationship between lethality of family history of prostate cancer in first-degree 
relatives and the aggressiveness of the prostate cancer has not been previously investigated in contem-
porary studies. This cohort demonstrates that there is no association between lethal prostate cancer 
family history and more aggressive disease of PCa. There was no difference in BCR or adjuvant therapy 
among the three cohorts. In comparison to the other groups, the NFH group had more LVI (p = 0.048). 
Furthermore, this finding may suggest that those men with a family history of PCa were potentially 
more aggressively screened or sought treatment earlier in their disease course. Additionally, this finding 
appears to lend support to a previous finding by Kupelian et al. who, in a systematic analysis of 4,112 
patients with stage T1-3 PCa, observed that family history of PCa was not an independent predictor 
of biochemical relapse10. Kupelian’s study has shown that men with a positive family history of PCa 
Figure 1. Kaplan-Meier analysis graph for the rate Biochemical Recurrence (BCR) stratified by family 
history among the no family history (NFH), family history nonlethal (FH) and family history died (FHD) 
groups.
Covariates
Hazard 
ration 
(HR)
95% Confidence 
Interval (CI)
p-valueLower Upper
Family history 
prostate cancer .250
 Non-Lethal .520 .200 1.354 .181
 Lethal .331 .045 2.457 .280
Age .976 .931 1.024 .324
Race (non-Caucasian) .487 .211 1.120 .090
D’Amico Risk Group <0.001*
 Intermediate risk 4.135 1.129 15.145 .032*
 High risk 19.723 5.837 66.639 <0.001*
Table 3. Multivariate logistic regression for biochemical recurrences adjusting for family history prostate 
cancer, age, race, and D’Amico risk group. *statistically significant (p < 0.05).
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presented with more favorable disease and that the overall impact of family history of PCa on prognosis 
was minimal10. Other studies have corroborated the minimal impact family history of PCa has on disease 
aggressiveness and recurrence11–14.
In this study, we specifically sought to determine if the death of a first-degree relative from PCa, as 
opposed to just presence of family history, is associated with more aggressive PCa clinically or pathologi-
cally. Limitations of this study include a relatively small number of patients with relative short follow-ups 
for a documented family history of lethal PCa. Although the cohorts are well matched and similar in 
most of the baseline characteristics, these men were all treated at a tertiary referral center, and there is 
likely inherited selection bias in this patient population. In addition, although we indicate which patients 
had primary relatives with PCa specific mortality, we do not know the age at which these family members 
died – a man who passed away at age 85 from PCa may have had inherently different disease biology 
from a man who died of PCa in his 60 s. Lastly, although the cohorts within this study are comparable 
based on baseline demographics and clinical parameters, the results may not be externally applicable in 
all instances. This population is composed of patients from the West Coast of the United States, particu-
larly Southern California, and may not account for genetic variants abroad.
Conclusions
In this institutional cohort, patients with a first-degree relative who died of PCa do not appear to have 
higher-risk, aggressive PCa at diagnosis or a worse outcome after radical prostatectomy, compared to 
men without a family history or a non-lethal family history of PCa. Future studies with more patients 
and correlation with specific inherited genetic defects will be critical to fully understand the association 
of inherited PCa lethality and high-risk, aggressive PCa.
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